Lung cancer drug sotorasib passes safety review in chinese patients
NCT ID NCT07143513
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This study looked at the safety of the drug sotorasib in 102 Chinese adults with a specific type of advanced lung cancer (KRAS G12C-mutated NSCLC) who had already tried other treatments. Researchers tracked side effects like liver problems, lung inflammation, and kidney issues. The goal was to understand how safe the drug is in this group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Boao Evergrande International Hospital
Qionghai, Hainan, 571400, China
-
Boao Super Hospital
Qionghai, Hainan, 571499, China
-
Ruijin-Hainan Hospital Shanghai Jiao Tong University School of Medicine Hainan Boao Research Hospital
Qionghai, Hainan, 57400, China
Conditions
Explore the condition pages connected to this study.